Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13779687 | 0.85 | AR (0.59) | ARKDM4EALDH1A1L3MBTL1SLC22A12 | |
| SCHEMBL4197135 | 0.79 | AR (0.48) | ARKDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL4206255 | 0.78 | AR (0.57) | ARKDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL177449 | 0.77 | AR (0.53) | ARKDM4EALDH1A1L3MBTL1NR3C1 | |
| SCHEMBL4192800 | 0.75 | AR (0.52) | ARKDM4EALDH1A1L3MBTL1NR3C1 | |
| SCHEMBL4163780 | 0.75 | AR (0.72) | ARHTR2ASLC6A4KCNH2SLC22A12 | |
| SCHEMBL4168834 | 0.75 | AR (0.72) | ARHTR2ASLC6A4KCNH2SLC22A12 | |
| SCHEMBL4171318 | 0.74 | AR (0.58) | ARHTR2ASLC6A4KCNH2SLC22A12 | |
| SCHEMBL27376804 | 0.73 | AR (0.52) | ARKDM4EALDH1A1L3MBTL1NR3C1 | |
| SCHEMBL410587 | 0.73 | TRPV4 (0.57) | ARKDM4EALDH1A1SLC22A12TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| WO-2007017754-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | AR 1/4885KDM4E 1054/4885ALDH1A1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.